The Society for Neuroscience annual meeting, which took place last week in Chicago, IL, is a place where the latest preliminary data in neuroscience is presented. True to form, there was an interesting abstract presented by Fernando Pagan, M.D. and colleagues from Georgetown University Hospital which suggested a potential treatment for those with Parkinson’s disease (PD). At the heart of the presentation, Dr. Pagan and colleagues reported that in a small trial, an anti-cancer drug called nilotinib was able to reverse both the movement symptoms and cognitive decline of people with PD involved in the study.
How do we capture rising stars in science and encourage them to focus their attention on Parkinson’s? This is a question that PDF — in its quest to help solve, treat and end PD — has been evaluating since its creation 60 years ago. In fact, PDF’s focus on catching rising stars in PD is the reason why we have prioritized funding for the training of early-career neurologists — more than 100 of them over the years — in PD research and care. It is also the reason we have supported the research of more than 250 early-career basic scientists over the same… Read More
A few weeks ago, I attended my first American Academy of Neurology (AAN) meeting, which was held in Washington, DC. This was the 67th annual meeting of the AAN, which brings together 10,000 neurologists and neuroscientists working to bring the best patient care and innovative research to the field of neurology. What should the PD community know about this gathering of professionals fighting their disease? Among the many highlights, here are a few of the more notable ones:
Which part of living with Parkinson’s disease should be the priority for scientists to study? For Diane Cook the answer is: cognitive issues. She submitted her answer through the Second Annual PDF Community Choice Research Awards survey. Now she is urging you to share yours by Thursday, April 30. Diane worked closely with PDF to develop the first Community Choice Research Awards survey last year, which are a “people’s choice” for PD research grants. The ProjectSpark Foundation run by Diane’s children donated funds for the awards. Hear from Diane about why the “people’s choice” awards are critical for PD research, why she… Read More
When 30,000 neuroscientists gather together to talk about the brain, what can we learn about Parkinson’s disease? Our team found out at the latest meeting of the Society for Neuroscience (SfN) meeting in Washington, DC, which took place in November. At the meeting, PDF’s James Beck, Ph.D., VP for Scientific Affairs, and Beth Vernaleo, Ph.D., Senior Manager, Research Programs, were joined by PDF Research Advocates Todd Hebb and Paul Zimmet, D.D.S., both of whom live with PD. (Drs. Zimmet and Vernaleo are pictured inset).
Thank you, on behalf of the Board of Directors, for those of you who have supported the Parkinson’s Disease Foundation this year, including those who have donated to this month’s special $500,000 challenge. Because of you, we have raised over $150,000 so far toward our goal, and every single gift will be doubled. As a scientist, your support gives me hope. I spent many years working with the nation’s largest biomedical research agency, the National Institutes of Health (NIH), to award billions of dollars in grants for neuroscience research, including Parkinson’s. And I knew of PDF’s reputation for supporting the next generation of… Read More